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AbstrAct
Background Atrial fibrillation (AF) is associated with 
left ventricular (LV) systolic dysfunction which may 
improve after AF ablation. We hypothesised that increased 
ventricular irregularity, as measured by R-R dispersion on 
the baseline ECG, would predict improvement in the left 
ventricular ejection fraction (LVEF) after AF ablation.
Methods Patients with LVEF <50% at two US centres 
(2007–2016), having both a preablation and postablation 
echocardiogram or cardiac MRI, were included. LVEF 
improvement was defined as absolute increase in LVEF 
by >7.5%. Multivariable logistic regression (restricted 
to echocardiographic/ECG variables) was performed to 
evaluate predictors of LVEF improvement.
Results Fifty-two patients were included in this study. 
LVEF improved in 30 patients (58%) and was unchanged/
worsened in 22 patients (42%). Those with versus 
without LVEF improvement had an increased baseline 
R-R dispersion (645±155 ms vs 537±154 ms, p=0.02, 
respectively). The average baseline heart rate in all 
patients was 93 beats per minute. After multivariable 
logistic regression, increased R-R dispersion (OR 
1.59, 95% CI 1.00 to 2.55, p=0.03) predicted LVEF 
improvement.
Conclusions Increased R-R dispersion on ECG was 
independently associated with improved systolic function 
after AF ablation. This broadens the existing knowledge 
of arrhythmia-induced cardiomyopathy, demonstrating 
that irregular electrical activation (as measured by 
increased R-R dispersion on ECG) is associated with a 
cardiomyopathy capable of improving after AF ablation.
IntRoduCtIon
Arrhythmia-induced cardiomyopathy (AIC) 
is defined as left ventricular (LV) systolic 
dysfunction occurring as a result of a persis-
tent cardiac arrhythmia. Although classi-
cally attributed to fast heart rates in tachyar-
rhythmias, frequent premature ventricular 
contractions (PVCs), which are usually not 
associated with tachycardia,1 as well as persis-
tent atrial fibrillation (AF), in the absence 
of tachycardia (ie, rate-controlled AF),2 can 
also be associated with LV systolic dysfunc-
tion. This raises the possibility that, apart 
from traditional explanations like loss of 
atrioventricular synchrony and atrial contrac-
tion (ie, the ‘atrial kick’), or associated 
valvular regurgitation, the irregular sequence 
of ventricular cycle lengths itself can lead to 
haemodynamic impairment in AF. This could 
then trigger reduced cardiac output and 
subsequent neurohormonal activation that 
can result in LV systolic dysfunction.2 3
It is often unclear whether AF is the result 
of an underlying cardiomyopathy (primary 
cardiomyopathy) or an actual cause of the 
cardiomyopathy (primary arrhythmia). Some 
clues that may be suggestive of a primary 
AIC include rapid AF ventricular response 
or young, otherwise healthy patients with no 
other apparent underlying cause for cardiac 
disease. Additionally, tachycardia-induced 
cardiomyopathy (TIC) is associated with 
relatively smaller LV dimensions compared 
with those with idiopathic dilated cardiomy-
opathy.4 However, severe LV enlargement 
does not exclude the possibility of TIC, and 
AF and heart failure often coexist in patients 
with multiple comorbidities, several of which 
are shared risk factors (eg, hypertension, 
diabetes, ischaemic heart disease and valvular 
Key questions
What is already known about this subject?
 ► Catheter ablation is associated with improvement in 
left ventricular (LV) ejection fraction in certain pa-
tients with cardiomyopathy.
What does this study add?
 ► To the best of our knowledge, this is the first study 
in humans demonstrating that increased ventricular 
irregularity, which was assessed by the R-R disper-
sion on ECG, is associated with improvement in LV 
ejection fraction after atrial fibrillation ablation.
How might this impact on clinical practice?
 ► The readily available measurement of ECG R-R dis-
persion may help to identify those patients most 
likely to derive LV systolic function improvement 
after catheter ablation.
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heart disease) for both AF and heart failure.5 Therefore, 
the distinction between a primary AIC due to AF and a 
primary cardiomyopathy causing AF becomes increas-
ingly challenging. Identifying those with a primary AIC 
has important implications, as an aggressive rate and 
rhythm control strategy in these patients would presum-
ably result in improvement in their cardiomyopathy.
We hypothesised that greater R-R interval dispersion 
might be a marker for an arrhythmia-induced cardiomy-
opathy and therefore also identify patients who would 
recover systolic function post-AF ablation.6
MetHods
study patients
We reviewed the Minneapolis VA Health Care System and 
University of California, Los Angeles (UCLA) AF ablation 
databases (2007–2016), including patients with complete 
transthoracic echocardiographic (TTE) or cardiac MRI 
studies before (within 1 year) and after (>5 weeks) AF 
ablation. The latter was chosen to allow time for reverse 
remodelling on restoration of sinus rhythm following AF 
ablation. Patients with an LVEF ≥50% were excluded. All 
patients underwent pulmonary vein isolation using radi-
ofrequency ablation with or without left atrial ablation 
for complex fractionated atrial electrograms.
echocardiographic and cardiac MRI measurements of LV 
variables
The two-dimensional (2D) echocardiographic studies, 
including chamber quantification measurements, were 
performed by experienced cardiac sonographers and 
interpreted and verified by cardiologists certified in 2D 
echocardiography. Variables of LV function that were 
measured included LV internal diameter during end-di-
astole (LVIDd), LV internal diameter during end-systole 
(LVIDs), LVEF and left atrial diameter. Measurements 
were performed according to the American Society of 
Echocardiography chamber quantification guidelines.7 
All cardiac MRI studies were performed on Siemens 
Prisma 3T or Siemens Avanto 1.5T MRI scanners 
(Siemens Healthineers, Malvern, Pennsylvania, USA), 
with horizontal long axis steady-state free precession 
images of the right and left ventricles reviewed on a dedi-
cated GE-PACS workstation. Images were reviewed by a 
cardiovascular radiologist with 10 years of experience. 
Measurements were performed three times with the 
mean selected and recorded.
eCG measurements
R-R dispersion was measured as the difference between 
the longest and shortest R-R interval on the single, most 
recent ECG preceding AF ablation that demonstrated 
AF. This was then corrected for a heart rate of 70 beats 
per minute (bpm) using the formula for corrected R-R 
dispersion which is (heart rate/70 bpm)*R-R dispersion. 
The longest or shortest R-R interval could involve a PVC 
if present.
definitions
Improvement in LVEF was defined as >7.5% absolute 
increase in LVEF in comparison to the pre-AF abla-
tion imaging study. A >7.5% cut-off was used given the 
constraint of previously reported ~7.5% interobserver 
variability in the measurement of 2D ejection fraction 
(EF).8 Consequently, LVEF that improved by ≤7.5% 
compared with the pre-AF ablation imaging study was 
categorised as unchanged or worsened.
statistical analysis
Continuous and categorical variables were summarised as 
mean±SD and frequency (%), respectively. Patients were 
categorised into two groups according to whether or not 
LVEF improved by >7.5%. The groups were compared 
using the Pearson’s χ2 test for categorical variables and 
the Student’s t-test for continuous variables. Changes 
in pre-AF versus post-AF ablation echocardiographic or 
cardiac MRI parameters were compared using the paired 
t-test. All p values were two sided with significance of 
<0.05. Univariable analysis was performed on collected 
clinical data and stratified by patients with and without 
LVEF improvement. Multivariable logistic regression 
(restricted to only echocardiographic and ECG variables 
with p<0.10 due to the small sample size) was performed 
to calculate ORs of LVEF improvement. Model perfor-
mance was analysed using the area under the receiver 
operating curve (C-statistic). Statistical analyses were 
performed using JMP version 14.1.0 (SAS Institute, Cary, 
North Carolina, USA).
This study was approved by the Institutional Review 




Between 1 January 2007 and 31 December 2015, a total of 
69 out of 252 consecutive patients undergoing AF ablation 
at the Minneapolis VA Medical Center had LV dysfunc-
tion (LVEF <50%) on a preablation echocardiogram 
(TTE) within 1 year. Of these, a total of 42 had postab-
lation imaging studies and were therefore included in 
this analysis. We included an additional 10 patients from 
the UCLA AF ablation database (2012 through 2017) 
that had both preablation and postablation cardiac MRI 
(n=8) or echocardiographic data (n=2). The total sample 
size was 52 patients. All were men.
Baseline demographic and clinical characteristics in 
the study population as a whole and in the subgroups 
of patients with improved and not improved LVEF after 
AF ablation are presented in table 1. The mean age of 
the study group was 63±8 years and all patients were 
men. Sixty per cent of patients had either persistent 
or long-standing persistent AF, and the remaining 
had paroxysmal AF. Nearly half (42%) had ischaemic 
heart disease. The mean heart rate was 93 bpm, which 
is satisfactory according to current guidelines, making 
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Table 1 Baseline characteristics in the study population as a whole, stratified by postablation response in LVEF (>7.5%)
Variables All patients, n=52 LVEF improved, n=30
LVEF
not improved, n=22 P value*
Age (years) 63±8 63±8 62±7 0.83
Male (%) 100 100 100 1.00
LVEF (%) 36±8 36±8 36±9 0.70
Hypertension (%) 83 73 95 0.04
Diabetes mellitus (%) 12 13 9 0.64
COPD (%) 21 20 23 0.81
OSA (%) 35 23 50 0.05
Prior MI (%) 15 10 23 0.21
Ischaemic heart disease (%) 42 37 50 0.34
CHA2DS2VASc score 2.6±1 2.4±1 3.0±1 0.13
CRT or ICD (%) 12 7 18 0.24
Body mass index (kg/m2) 31±6 29±5 32±7 0.08
Persistent/long-standing AF (%) 60 57 64 0.62
Medications
  Beta blocker (%) 85 83 86 0.76
  ACEi/ARB (%) 67 60 77 0.19
  Spironolactone (%) 17 13 23 0.38
  Hydralazine and ISDN (%) 2 0 5 0.24
  Digoxin (%) 29 30 27 0.83
  Diuretics (%) 37 33 41 0.58
  Antiarrhythmic (%) 44 40 50 0.47
ECG/echocardiographic
  Heart rate (bpm) 93±20 97±22 89±16 0.15
  Corrected R-R dispersion (ms) 600±162 645±155 537±154 0.02
  LVIDd (mm) 58±8 54±6 58±8 0.03
  LVIDs (mm) 44±8 42±7 46±9 0.06
  LAD (mm) 49±9 48±9 50±8 0.18
  Valvular (%) 12 7 18 0.20
*Improved (ΔLVEF >7.5%) versus not improved.
ACEi, ACE inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker;COPD, chronic obstructive pulmonary disease;CRT, 
Cardiac Resynchronization Therapy; ICD, implantable cardioverter defibrillator; ISDN, isosorbide dinitrate; LVEF, left ventricular ejection 
fraction;LVIDd, left ventricular internal diameter during end-diastole; LVIDs, left ventricular internal diameter during end-systole; MI, 
myocardial infarction; OSA, obstructive sleep apnoea; bpm, beats per minute.
tachycardia-mediated cardiomyopathy less likely. A 
substantial proportion of patients had multiple comor-
bidities (table 1). Preablation medications included beta 
blockers in 85% of patients, an ACE inhibitors or an 
angiotensin II receptor blockers (ACEi/ARB) in 67%, 
antiarrhythmic agents in 44%, diuretics in 37%, digoxin 
in 29%, as well as spironolactone and the combination 
of hydralazine with isosorbide dinitrate combination 
in a minority of patients (table 1). The mean LVEF was 
36%±8%.
Periprocedural changes in cardiac chamber dimensions
Cardiac chamber measurements before and after AF abla-
tion in the study population as a whole, and also stratified 
by subsequent EF improvement, are presented in table 2. 
The mean LVEF significantly improved following AF abla-
tion in the whole study cohort as a whole (36%±8% vs 
47%±13%, p=0.002). For the whole group, there was also 
a statistically significant reduction in LVIDs (from 44±8 
mm to 40±9 mm, p=0.02). There were no statistically 
significant changes in other cardiac chamber measure-
ments (ie, left atrial diameter or LVIDd) with AF ablation 
(table 2).
In the subgroups stratified by LVEF improvement 
versus no LVEF improvement, there was a statistically 
significant reduction in LVIDs in the group with LVEF 
improvement before versus after AF ablation (from 42±7 
mm to 36±6 mm, p=0.001). In contrast, no significant 
change in LVIDs was seen in the group with unchanged 
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Table 2 Left ventricular measurements before and after AF ablation in the study population as a whole, stratified by post-AF 
ablation response in LVEF (>7.5%)
Variables
All patients, n=52 LVEF improved, n=30 LVEF not improved, n=22
Before After P value Before After P value Before After P value
LVEF, % 36±8 47±13 0.002 36±8 56±8 <0.001 36±9 36±9 0.74
LVIDd, mm 56±7 56±7 0.77 54±6 53±5 0.40 58±8 59±7 0.73
LVIDs, mm 44±8 40±9 0.02 42±7 36±6 0.001 46±9 45±8 0.74
LAD, mm 49±9 48±7 0.39 48±9 47±6 0.38 50±8 49±8 0.78
Values presented as mean±SD.
AF, atrial fibrillation; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; LVIDd, left ventricular internal diameter during end-
diastole; LVIDs, left ventricular internal diameter during end-systole.
Figure 1 Change in left ventricular ejection fraction (LVEF) 
after atrial fibrillation ablation based on the baseline R-R 
dispersion.
Table 3 Baseline chamber dimensions stratified by future 
outcomes
Outcome LVIDd LVIDs LAD
Improved LVEF (n=30) 54±6 42±7 48±9
Worsened/unchanged LVEF (n=22) 58±8 46±9 50±8
P value 0.02 0.07 0.53
No AF recurrence (n=26) 56±7 44±7 47±7
AF recurrence 56±8 43±9 51±10
P value 0.70 0.67 0.14
Symptoms improved (n=33) 55±6 43±7 47±7
Symptoms not improved (n=17) 58±8 45±7 52±7
P value 0.14 0.44 0.03
All measurements are expressed in millimetres.
AF, atrial fibrillation; LAD, left atrial diameter;LVEF, left ventricular 
ejection fraction; LVIDd, left ventricular internal diameter during 
end-diastole; LVIDs, left ventricular internal diameter during end-
systole.
or worsened LVEF. There were no other periprocedural 
changes in cardiac measurements (table 2).
Predictors of LVeF improvement after AF ablation
After a median (IQR) of 5.7 months (4–12 months), 
LVEF improved by >7.5% in 30 patients (58% of the 
study population) and was unchanged/worsened in 22 
patients (42%). Pre-AF and post-AF ablation LVEF was 
36%±8% vs 56%±8%, respectively (p<0.001), in patients 
with improved LVEF and 36%±9% vs 36%±9%, respec-
tively (p=0.74), in patients with unchanged/worsened 
LVEF (table 2).
Patients with improved LVEF after ablation were less 
likely to have hypertension or sleep apnoea (table 1). 
Those with versus without LVEF improvement had 
increased R-R dispersion (645±155 ms vs 537±154 ms, 
respectively, p=0.02) (table 1, figure 1) and smaller 
LVIDd (54±6 mm vs 58±8 mm, p=0.02) (table 3, figure 2). 
Other cardiac chamber dimensions were not associated 
with changes in LVEF. Multivariable analysis, restricted 
to echocardiographic and ECG variables (due to limita-
tions in the sample size of the study) having a univari-
able p<0.10 was performed. The candidate predictors 
satisfying p<0.05 after multivariable logistic regression 
included R-R dispersion by ECG (table 4), having an 
OR (95% CI) of 1.59 (1.00 to 2.55) (p=0.03) for LVEF 
improvement by 7.5%.
In a subgroup analysis of ischaemic (42%) versus 
non-ischaemic heart disease (58%), LVEF improvement 
occurred in 50% vs 63%, respectively (p=0.29). In this 
subgroup analysis, increased R-R dispersion remained 
a significant predictor of LVEF improvement in those 
without ischaemic heart disease (p<0.01), whereas statis-
tical significance was lost in those with ischaemic heart 
disease (online supplementary table 1).
Baseline R-R dispersion between patients with obstruc-
tive sleep apnoea (OSA) (628±194 ms) versus those 
without OSA (587±146 ms) was not statistically significant 
(p=0.43).
AF recurrence and symptom improvement at 1 year
At the 1-year follow-up period, 33 (66%) patients had 
symptom improvement (table 3). Among the cardiac 
chamber variables, an improvement in symptoms versus 
unchanged or worsened symptoms at 1 year had smaller 
left atrial diameter dimensions (47±7 mm vs 52±7 mm, 
p=0.03, respectively) (table 3). Symptoms improved in 
82% of those with EF improvement, versus only 45% 
of those without EF improvement (p=0.001) (data not 
shown).
At the 1-year follow-up period, 26 patients (50%) had 
no AF recurrences. Among the cardiac chamber variables, 
5Koene RJ, et al. Open Heart 2019;6:e000958. doi:10.1136/openhrt-2018-000958
Arrhythmias and sudden death
Figure 2 Change in LVEF after atrial fibrillation ablation 
based on baseline left ventricular internal dimension in 
diastole. LVEF, left ventricular ejection fraction; LVIDd, left 
ventricular internal diameter during end-diastole.
Table 4 Multivariable OR and 95% CIs for left ventricular 
EF improvement by 7.5% after catheter ablation for atrial 
fibrillation*
EF improvement by 7.5% (n=30)
Variables OR (95% CI) P value
R-R dispersion (per 100 unit 
increase)
1.59 (1.00 to 2.55) 0.03
LVIDd, mm (per 10 unit 
increase)
0.57 (0.10 to 3.17) 0.51
LVIDs, mm (per 10 unit 
increase)
0.78 (0.18 to 3.37) 0.74
*Restricted to echocardiographic and ECG variables only due 
to limited sample size, keeping all variables from table 1 with 
univariable p value <0.10.
EF, ejection fraction; LVIDd, left ventricular internal diameter during 
end-diastole; LVIDs, left ventricular internal diameter during end-
systole.
there was a trend toward AF recurrence being associated 
with larger left atrial dimensions (p=0.14) (table 4).
dIsCussIon
In this study, we found that increased ventricular irreg-
ularity, as measured by the R-R dispersion on the most 
recent ECG demonstrating AF preceding catheter abla-
tion, predicted LVEF improvement following AF ablation. 
Because AF ablation eliminates or reduces ventricular 
irregularity (by reducing AF burden), we can surmise 
that ventricular irregularity itself is a contributing factor 
to LV systolic dysfunction. In addition, smaller LVIDd 
on baseline cardiac imaging identified an increased like-
lihood for LVEF improvement. There was also a trend 
toward smaller baseline LVIDs and improved postab-
lation LVEF (p=0.06), suggesting that better baseline 
contractility might be an important predictor of postabla-
tion response. After multivariable analysis, increased R-R 
dispersion was the only statistically significant predictor 
of LVEF improvement among ECG and echocardio-
graphic variables. Perhaps, the principal finding of this 
study is that the R-R dispersion was measured using only 
a single ECG before AF ablation and may serve as a prac-
tical prediction guide. Similarly, LV dimensions which 
are readily available in most patients undergoing AF abla-
tion can serve to inform postablation outcomes. These 
findings may have important implications in the manage-
ment of patients with coexisting AF and heart failure by 
helping to identify those who may derive the most benefit 
from restoration of sinus rhythm with catheter ablation.
Mechanisms for AIC in rate-controlled AF have been 
postulated but are difficult to study in humans, who 
often have comorbidities or concomitant tachycardia.3 
It is speculated that irregular ventricular cycles result 
in reduced LV filling during short cycles that is incom-
pletely compensated for during long cycles, causing 
reduced cardiac output and subsequent neurohormonal 
activation, leading to adverse cardiac remodelling.2 A 
prior pacing study in a canine model showed that straight 
pacing (ie, regularly paced ventricular cycles) alone 
reduced cardiac output, but the addition of irregular 
ventricular cycles further reduced cardiac output by an 
additional 7%.8 Using isolated cardiac myocytes from 
rats, Ling et al found that irregular pacing compared 
with regular pacing over a 24-hour period resulted in a 
substantial decrease in sarcoplasmic reticulum Ca2+-AT-
Pase and phosphorylated phospholamban, both of which 
are associated with heart failure (figure 3).9 In LV samples 
obtained from patients with end-stage heart failure with 
either persistent AF or sinus rhythm, there was a decrease 
in several calcium-handling proteins observed in those 
with persistent AF but not in those who had sinus rhythm.9
Studies have demonstrated improvement in LVEF 
after catheter ablation in well rate-controlled patients. 
In a study of 58 consecutive patients with an LVEF <45% 
undergoing catheter ablation for AF, patients improved 
their LVEF by 17%±15% despite having adequate rate 
control defined as a heart rate <80 bpm on 48 hours 
telemetry preprocedure, and not surprisingly, those with 
poorly controlled heart rates had even greater improve-
ment of their LVEF by 23%±10%.10 A recent randomised 
controlled trial of 68 patients with adequate heart rate 
control demonstrated an improvement in LVEF of 
18%±13% in patients assigned to catheter ablation versus 
an LVEF change of 4.4%±13% in those assigned to a rate 
control strategy.11
The findings from our study and these other studies 
suggest that arrhythmia itself is a source of cardiomyop-
athy in AF independent of tachycardia. Eliminating the 
severity of arrhythmia, by way of reducing the R-R disper-
sion, is associated with improved LV systolic function. 
Because of this, one might hypothesise that patients with 
AF, heart failure and increased R-R dispersion should 
derive the most benefit from a catheter-based rhythm 
control therapeutic strategy.
Subject to the limitations of the study, these observa-
tions add to our understanding of the pathophysiology of 
AIC. This study may also help identify patients more likely 
to have an arrhythmia-induced or arrhythmia-worsening 
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Figure 3 Illustration of a cardiac myocyte featuring a 
number of calcium-handling proteins (A). Irregular pacing 
leading to a reduction in phosphorylated phospholamban 
and subsequent reduction in calcium transport into the 
sarcoplasmic reticulum (B), and irregular pacing leading 
to a reduction in SERCA and subsequent reduction in 
calcium transport into the sarcoplasmic reticulum (C). A1 
receptor, adenosine A1 receptor; AC, adenylyl cyclase; 
ACh, acetylcholine; ADO, adenosine; β-AR, beta adrenergic 
receptor; cAMP, cyclic AMP; CICR, calcium-induced calcium 
release; NCX, sodium–calcium exchanger; PKA, protein 
kinase A; PLB, phospholamban; RyR, ryanodine receptor; 
SERCA, sarcoplasmic sarcoplasmic/endoplasmic reticulum 
Ca2+ ATPase.
cardiomyopathy, and who may therefore derive benefit 
from treatment of the offending arrhythmia with cath-
eter ablation. We believe that these results are worthy of 
further investigation as they seem to add to our under-
standing of the factors contributing to LV impairment 
before and improvement after AF ablation.
There are several limitations in our study. First, it was 
retrospective and uncontrolled and is thus hypothesis 
generating rather than definitive. Second, because echo-
cardiograms or cardiac MRI are not routinely obtained 
after AF ablation, there may be selection bias. Third, 
echocardiographic or MRI measurements in individual 
patients were assessed on only two occasions, so we 
cannot say whether these changes remained consistent 
in the longer term in their direction or magnitude. Of 
the patients who qualified for our study based on having 
a low preablation LVEF, only ~60% had subsequent echo-
cardiograms to allow for comparison. Fourth, the sample 
size of patients was relatively small and included only 
men. Fifth, information about the burden of AF may 
have provided more insights into our findings. However, 
improvement in LVEF may indirectly show evidence of 
the clinical impact of ablation irrespective of knowing 
the AF burden. Sixth, the use of ACEi/ARB medications 
was 67%. This was relatively low for a population with 
impaired LV function, but was unlikely to have affected 
the main finding of our study. Finally, most patients were 
evaluated by echocardiography, and some might argue 
this commonly available tool is not the best way to assess 
cardiac function, particularly given the constraint of 
previously reported ~7.5% interobserver variability in the 
measurement of 2D-EF.8 Furthermore, fibrosis burden 
as determined by cardiac MRI has been shown to be an 
important predictor of ablation response in non-isch-
aemic cardiomyopathy,11 and this could provide further 
insight into our study.
ConCLusIons
In patients with heart failure undergoing AF ablation, 
both an increase in R-R dispersion on ECG and smaller 
LVIDd were associated with improvement in LVEF after 
catheter ablation. Increased R-R dispersion remained 
significant after adjustment for potential confounders 
and heart rate. This broadens the existing knowledge on 
AIC, particularly the notion that irregular electrical acti-
vation can cause cardiomyopathy and that the cardiomy-
opathy may improve with elimination of the irregularity 
using catheter ablation. These readily available measure-
ments may help to identify those patients most likely to 
derive LV systolic function improvement after catheter 
ablation.
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